OAM
SMMT icon

Oxford Asset Management’s Summit Therapeutics SMMT Stock Holding History

Oxford Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,535
Closed -$245K – 711
2025
Q2 		$245K Buy
+11,535
New +$263K 0.08% 384
2024
Q2 		– Sell
-27,080
Closed -$112K – 405
2024
Q1 		$112K Buy
+27,080
New +$108K 0.12% 223

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Oxford Asset Management's SMMT Position: Q3 2025 in Review

Oxford Asset Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 11,535 shares — an estimated $245K sold.

Oxford Asset Management first reported a position in SMMT in Q1 2024 and held it in 2 quarters. The position peaked at $245K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Oxford Asset Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Oxford Asset Management sold 11,535 Summit Therapeutics shares in Q3 2025, an estimated $245K.
  • Oxford Asset Management first reported a position in Summit Therapeutics in Q1 2024 and held it in 2 quarters.
  • Oxford Asset Management's Summit Therapeutics position peaked at $245K in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.